Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DOXYCHEL HYCLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DOXYCHEL HYCLATE.
AUREOMYCIN vs DOXYCHEL HYCLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic